Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PBI-410 |
Synonyms | |
Therapy Description |
PBI-410 is an antibody-drug conjugate (ADC) comprising an antibody targeting TROP2 linked to a camptothecin analogue, which potentially induces cytotoxicity against TROP2-expressing tumor cells and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 7168; Cancer Res (2023) 83 (7_Supplement): 1549). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PBI-410 | PBI 410|PBI410|GQ1010|GQ-1010|GQ 1010 | PBI-410 is an antibody-drug conjugate (ADC) comprising an antibody targeting TROP2 linked to a camptothecin analogue, which potentially induces cytotoxicity against TROP2-expressing tumor cells and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 7168; Cancer Res (2023) 83 (7_Supplement): 1549). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06384807 | Phase Ib/II | PBI-410 | A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors | Recruiting | USA | 0 |